Retrospective Cohort Study: Ledipasvir-Sofosbuvir With/Without Ribavirin for Chronic Hepatitis C Post-Liver...

Area of Science:

• Hepatology
• Virology
• Transplantation Medicine

Background:

• Hepatitis C virus (HCV) infection is a leading cause of liver transplantation in the US and Europe.
• Recurrent HCV infection post-transplant significantly increases patient morbidity and mortality.
• Effective strategies to prevent HCV recurrence are critical for improving transplant outcomes.

Purpose of the Study:

• To evaluate the efficacy of ledipasvir-sofosbuvir (LDV/SOF) in achieving sustained virologic response (SVR) in post-liver transplant patients with recurrent HCV.
• To assess SVR rates in patients treated with different durations of LDV/SOF therapy.

Main Methods:

• Retrospective cohort study at a major academic medical center.
• Inclusion of HCV genotype 1 or 4 positive patients post-liver transplant.
• Analysis of patients receiving 12 weeks of LDV/SOF (with or without ribavirin) versus 24 weeks of LDV/SOF alone.

Main Results:

• Twenty-nine patients received 12 weeks of LDV/SOF, and 32 patients received 24 weeks of LDV/SOF.
• 100% SVR rate was achieved in the 12-week treatment group (29/29 patients).
• 100% SVR rate was achieved in the 24-week treatment group (32/32 patients).

Conclusions:

• Ledipasvir-sofosbuvir (LDV/SOF) is highly effective in treating recurrent HCV in liver transplant recipients.
• Both 12-week and 24-week LDV/SOF regimens resulted in complete viral eradication.
• High SVR rates with LDV/SOF offer a promising solution for managing post-transplant HCV infection.